Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
31 Mayo 2024 - 12:00AM
UK Regulatory
Data from the PRECISION study of aprocitentan to be presented at
the European Society of Hypertension Annual Meeting 2024
Allschwil, Switzerland – May 31, 2024
Idorsia Ltd (SIX: IDIA) today announced that data from the Phase
3 study of aprocitentan, Idorsia’s endothelin receptor antagonist,
will be presented by Prof. Krzysztof Narkiewicz, MD, PhD, at the
European Society of Hypertension’s
33rd European Meeting of Hypertension
and Cardiovascular Protection, taking place in Berlin, Germany, May
31 – June 3, 2024.
An oral presentation is scheduled for Sunday, June 2 (09:05 –
09:15 CEST) in Convention Hall I C, as part of the “Clinical
Studies” session, entitled “Blood pressure control with
aprocitentan in resistant hypertension”. The presentation focuses
on a pre-planned analysis evaluating the efficacy of aprocitentan
on the percentage of patients with controlled blood pressure
according to hypertension guidelines at different timepoints during
the Phase 3 PRECISION study. The abstract can be found here.
A poster presentation is scheduled for Saturday, June 1 (18:50 –
18:55 CEST) as part of the session “Moderated E-poster session 7 -
Clinical studies”, entitled “Effect of high dose aprocitentan in
patients with resistant hypertension not controlled by low dose”.
The presentation focuses on a post-hoc exploratory analysis
evaluating the observed long-term benefit of increasing to a higher
dose of aprocitentan (25 mg) in patients not achieving a blood
pressure control after 4 weeks on the lower dose (12.5 mg). The
abstract can be found here.
Notes to the editor
About aprocitentan
Aprocitentan is Idorsia’s once-daily, orally active, dual
endothelin receptor antagonist, which inhibits the binding of ET-1
to ETA and ETB receptors. In May
2022, Idorsia announced positive top-line results of the Phase 3
PRECISION study with aprocitentan for the treatment of
patients with resistant hypertension. Detailed results were
published in The Lancet and presented as a
Late-Breaking Science presentation during the American Heart
Association (AHA) Scientific Sessions in November 2022. More
details and commentary can be found in the dedicated press
release and an investor webcast featuring Prof.
Markus Schlaich, an investigator in PRECISION.
On March 19, 2024, aprocitentan was approved as TRYVIO in the
US, with availability planned for H2 2024. On April 25, 2024,
Idorsia received a positive opinion for aprocitentan (as JERAYGO™)
from the Committee for Medicinal Products for Human Use (CHMP) as a
treatment of resistant hypertension. A CHMP positive opinion is one
of the final steps before marketing authorization can be granted by
the European Commission; a final decision is expected approximately
two months after publication of the CHMP opinion.
About Prof. Krzysztof Narkiewicz, MD, PhD
Professor Krzysztof Narkiewicz is the Head of the Department of
Hypertension and Diabetology, Medical University of Gdansk, Gdansk,
Poland. His research has been focused on the role of the
sympathetic nervous system and metabolic factors in regulation of
cardiovascular function in physiological and pathological states,
and on prevention and treatment of cardiometabolic diseases
including hypertension, diabetes, coronary artery disease,
congestive heart failure and obstructive sleep apnea. He has
published over 700 full-text publication; (> 39 000 citations;
h-index: 69). He was the President of the Scientific Council of the
European Society of Hypertension (2009-2011). He was a member of
the Task Force for the Management of Arterial Hypertension of the
European Society of Hypertension (ESH) and of the European Society
of Cardiology (ESC) preparing the 2007, 2013 and 2018 Guidelines
for the Management of Arterial Hypertension. He also contributed to
the 2023 ESH hypertension guidelines.
Prof. Krzysztof Narkiewicz serves as a consultant to
Idorsia.
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see
more opportunities and we want to help more patients. In order to
achieve this, we will develop Idorsia into a leading
biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub –
Idorsia is specialized in the discovery, development and
commercialization of small molecules to transform the horizon of
therapeutic options. Idorsia has a 25-year heritage of drug
discovery, a broad portfolio of innovative drugs in the pipeline,
an experienced team of professionals covering all disciplines from
bench to bedside, and commercial operations in Europe and North
America – the ideal constellation for bringing innovative medicines
to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol:
IDIA) in June 2017 and has over 750 highly qualified specialists
dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate
Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123
Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain "forward-looking
statements", relating to the company's business, which can be
identified by the use of forward-looking terminology such as
"estimates", "believes", "expects", "may", "are expected to",
"will", "will continue", "should", "would be", "seeks", "pending"
or "anticipates" or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions
of the company's investment and research and development programs
and anticipated expenditures in connection therewith, descriptions
of new products expected to be introduced by the company and
anticipated customer demand for such products and products in the
company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject
to certain risks, uncertainties and assumptions. Many factors could
cause the actual results, performance or achievements of the
company to be materially different from any future results,
performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or
expected.
Idorsia (LSE:0RQE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Idorsia (LSE:0RQE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
